DNB//Back Bay — FEATURED NEWS Home — Back Bay Life Science Advisors

Posts tagged DNB//Back Bay

As Money Pours Into Weight Loss Drugs, Physicians Prioritize Efficacy, Access

With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.

Back Bay Life Science AdvisorsFebruary 28, 2025DNB Bank, DNB//Back Bay, Carnegie

Obesity Drug Development: Still Room to Grow

Analyst ReportDNB//Back BayFebruary 17, 2025DNB//Back Bay, Healthcare Equity Analyst Reports, Blood Brain Barrier, CNS Development

Breaching the Blood-Brain Barrier - CNS Therapeutic Development

Analyst ReportDNB//Back BayNovember 12, 2024DNB//Back Bay, Healthcare Equity Analyst Reports, Blood Brain Barrier, CNS Development

DNB Bank ASA acquires Carnegie

DNB//Back BayOctober 21, 2024DNB Bank, DNB//Back Bay, Carnegie

DNB Markets, Back Bay Life Science Advisors and KD Pharma

Transaction UpdatesDNB//Back BayOctober 10, 2024M&A, Transactions, DNB//Back Bay